Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gain Therapeutics Inc GANX

Healthcare Biotechnology
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug... see more

Recent & Breaking News (NDAQ:GANX)

Gain Therapeutics Announces Proposed Public Offering

GlobeNewswire November 20, 2023

Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

GlobeNewswire November 14, 2023

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

GlobeNewswire October 4, 2023

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

GlobeNewswire September 25, 2023

Gain Therapeutics to Present at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference

GlobeNewswire September 20, 2023

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

GlobeNewswire September 12, 2023

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

TheNewsWire August 29, 2023

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model

GlobeNewswire August 28, 2023

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

GlobeNewswire August 10, 2023

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson's Disease and Movement Disorders®

GlobeNewswire August 7, 2023

Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference

GlobeNewswire July 31, 2023

Gain Therapeutics to Present at the Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

GlobeNewswire May 12, 2023

Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson's Disease

GlobeNewswire May 3, 2023

Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

GlobeNewswire April 12, 2023

Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

GlobeNewswire March 29, 2023

Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update

GlobeNewswire March 23, 2023

Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders

GlobeNewswire March 22, 2023

Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program

GlobeNewswire March 21, 2023

Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

GlobeNewswire March 9, 2023